Molecular analysis in the lot with patients younger than 60 years old showed a significantly higher proportion of anomalies with favorable prognosis (6 cases AML-ETO, PML-RARA 5 cases, 1 case NPM1) compared to the presence of mutations with poor prognosis (5 cases FLT3 -ITD, 2 cases FLT3-ITD + NPM1, 1 case with mutations in WT1 gene). This evidence concerns the gene NPM1 and acute myeloid leukemia.